Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.
Department of Pulmonology, University of Lübeck, Lübeck, Germany.
Anticancer Res. 2019 Nov;39(11):6355-6358. doi: 10.21873/anticanres.13847.
BACKGROUND/AIM: Pneumonitis is a serious complication after radiotherapy of breast cancer. This study aimed to identify its prevalence and potential risk factors.
A total of 606 patients irradiated following breast-conserving surgery or mastectomy were retrospectively analyzed. In patients developing pneumonitis, radiation and clinical parameters were investigated to identify potential risk factors.
Eleven patients (1.8%) developed a pneumonitis grade ≥2. Mean doses to the ipsilateral lung were >7 Gy in 5 patients (45%). Of the other patients, 5 had a chronic inflammatory disease. Six patients (55%) had another malignancy (4 previous contralateral breast cancers, 1 previous ovarian and thyroid cancer, 1 synchronous carcinoma-in-situ (pTis) at the contralateral breast). Five patients (45%) received chemotherapy including taxanes and 4 patients (36%) received trastuzumab.
The prevalence of pneumonitis was 1.8%. Potential risk factors included mean radiation dose to ipsilateral lung >7 Gy, systemic treatment with taxanes or trastuzumab, chronic inflammatory disease and history of another malignancy.
背景/目的:肺炎是乳腺癌放疗后的一种严重并发症。本研究旨在确定其发生率和潜在的危险因素。
回顾性分析了 606 例接受保乳手术或乳房切除术放疗的患者。在发生肺炎的患者中,研究了放射治疗和临床参数,以确定潜在的危险因素。
11 名患者(1.8%)发生≥2 级肺炎。5 名患者(45%)同侧肺的平均剂量>7 Gy。其他患者中,有 5 人患有慢性炎症性疾病。6 名患者(55%)患有另一种恶性肿瘤(4 例对侧乳腺癌、1 例卵巢和甲状腺癌、1 例对侧乳腺癌同时原位癌(pTis))。5 名患者(45%)接受了包括紫杉醇类药物在内的化疗,4 名患者(36%)接受了曲妥珠单抗治疗。
肺炎的发生率为 1.8%。潜在的危险因素包括同侧肺的平均放射剂量>7 Gy、紫杉醇类药物或曲妥珠单抗的全身治疗、慢性炎症性疾病和另一种恶性肿瘤史。